← Leaderboards
Rodolphe Barrangou
Colorado State University
$1,320,899
Attributed
$3,825,497
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $994.5K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,825,497 · 2
By mechanism
R01$3,551,096 · 1
R41$274,401 · 1
Top collaborators
- Zaid Abdo7 shared
- Gregg A Dean7 shared
- Matthew Harrison Foley1 shared
Most similar at Colorado State University
Same institution · by research overlap
- Gregg A Dean$12,732,502
- Zaid Abdo$1,905,191
- Elizabeth P Ryan$1,684,040
Others in their field
Other Emerging Leaders on “Immunize”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmunizeMicrobiomeVirusEngineeringMouse ModelClustered Regularly Interspaced Short Palindromic RepeatsCrispr/Cas TechnologyComparative EfficacyDeveloping CountriesClinical TrialsAntigensAttenuatedAffectCountryAntibiotic ResistanceChildCellsAnimalsCessation Of Life5 Year OldAntibody ResponseCapsidCapsid ProteinsAdjuvant
Grant awards (8)
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$720,054
R01 · FY2024 · AI
Enhancing E. coli Nissle colonization with CRISPR-Cas immunity$274,401
R41 · FY2024 · DK
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$758,912
R01 · FY2023 · AI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$679,126
R01 · FY2022 · AI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$11,389
R01 · FY2022 · AI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$681,022
R01 · FY2021 · AI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$691,456
R01 · FY2020 · AI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$9,137
R01 · FY2020 · AI